Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ketamine may rely on opioid receptors for antidepressive effect

Publish date:: May 23, 2019

Key clinical point: Understanding ketamine’s mechanism could enhance patient safety.

Major finding: Pretreatment with naltrexone undermined ketamine’s activity.

Study details: Randomized, controlled trial (n = 11).

Disclosures: The study was funded by the National Institutes of Health, Spectrum, the Brain and Behavior Research Foundation, and Stanford Bio-X. Dr. Williams had no disclosures.

Citation:

REPORTING FROM APA 2019

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Depression

Rap music mention of mental health topics more than doubles,

Social factors predicted peripartum depressive symptoms in Black women with HIV,

Mental health risks rise with age and stage for gender-incongruent youth,

Teen affective disorders raise risk for midlife acute MI,

Divergent COVID-19 mental health impacts seen in Spain and China,